These two different co-occurring mutations in KRAS-mutated LUADs lead to almost opposite microenvironments, demonstrating the critical impact of co-occurring mutations on the immune-related characteristics in NSCLC and the promising opportunities that interactions between co-occurring mutations may foster the improvement of prediction algorithms for cancer immunotherapy. This evidence concerns the gene KRAS and non-small cell lung carcinoma.